Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 7, 2011, Pages 1695-1698

  Igue, Raouf ^a   Potvin, Stéphane ^b,c   Bah, Ramatoulaye ^a   Stip, Emmanuel ^b,c   Bouchard, Roch Hugo ^d   Lipp, Olivier ^b,c   Gendron, Alain ^c,e,f   Kouassi, Edouard ^a,b,c  

^a UNIVERSITY OF MONTREAL   (Canada)

^b CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

^e ASTRAZENECA   (United Kingdom)

^f UNIVERSITÉ LAVAL   (Canada)

Author keywords

Positive symptoms; Quetiapine; Schizophrenia; Soluble interleukin 2 receptor; Substance use disorders

Indexed keywords

AMPHETAMINE; COCAINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; NEUROLEPTIC AGENT; OLANZAPINE; PHENCYCLIDINE; PSYCHEDELIC AGENT; QUETIAPINE; RISPERIDONE; SOLUBLE INTERLEUKIN 2 RECEPTOR; ZIPRASIDONE;

ADULT; ALCOHOLISM; ARTICLE; BODY MASS; CALGARY DEPRESSION SCALE FOR SCHIZOPHRENIA; CANNABIS ADDICTION; CLINICAL ARTICLE; COCAINE DEPENDENCE; COMORBIDITY; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MALE; MENTAL DISEASE; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PROTEIN BLOOD LEVEL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SUBSTANCE ABUSE;

ADULT; AFFECTIVE SYMPTOMS; ANTIPSYCHOTIC AGENTS; COMORBIDITY; CYTOKINES; DIBENZOTHIAZEPINES; FEMALE; HUMANS; INTERLEUKIN-6; MALE; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-2; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 79961128129     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.05.011     Document Type: Article

References (37)

1. Addington D., Addington J., Maticka-Tyndale E., Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 1992, 6:201-208.
2. Akiyama K. Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr Res 1999, 37:97-106.
3. Bian Q., Kato T., Monji A., Hashioka S., Mizoguchi Y., Horikawa H., et al. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:42-48.
4. Cheer S.M., Wagstaff A.J. Quetiapine: a review of its use in the management of schizophrenia. CNS Drugs 2004, 18:173-199.
5. Drake R.E., Osher F.C., Noordsy D.L., Hurlbut S.C., Teague G.B., Beaudett M.S. Diagnosis of alcohol use disorders in schizophrenia. Schizophr Bull 1990, 16:57-67.
6. Drzyzga L., Obuchowicz E., Marcinowska A., Herman Z.S. Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 2006, 20:532-545.
7. Fagerström K.O., Schneider N.G. Measuring nicotine dependence: a review of the Fagerström Tolerance Questionnaire. J Behav Med 1989, 12:159-182.
8. Haack M., Hinze-Selch D., Fenzel T., Kraus T., Kühn M., Schuld A., et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999, 33:407-418.
9. Hinze-Selch D., Pollmächer T. In vitro cytokine secretion in individuals with schizophrenia: results, confounding factors, and implications for further research. Brain Behav Immun 2001, 15:282-318.
10. Juge-Aubry C.E., Somm E., Giusti V., Pernin A., Chicheportiche R., Verdumo C., et al. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 2003, 52:1104-1110.
11. Kavannagh D.J., McGrath J., Saunders J.B., Dore G., Clark D. Substance misuse in patients with schizophrenia. Drugs 2002, 62:743-755.
12. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
13. Kim Y.K., Kim L., Lee M.S. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res 2000, 44:165-175.
14. Kim D.J., Kim W., Yoon S.J., Go H.J., Choi B.M., Jun T.Y., et al. Effect of risperidone on serum cytokines. Int J Neurosci 2001, 111:11-19.
15. Kluge M., Schuld A., Schacht A., Himmerich H., Dalal M.A., Wehmeier P.M., et al. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology 2009, 34:118-128.
16. Laruelle M., Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol 1999, 13:358-371.
17. Latvala J., Hietala J., Koivisto H., Järvi K., Anttila P., Niemelä O. Immune responses to ethanol metabolites and cytokine profiles differentiate alcoholics with or without liver disease. Am J Gastroenterol 2005, 100:1303-1310.
18. Maes M., Meltzer H.Y., Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994, 89:346-351.
19. Maes M., Bosmans E., Ranjan R., Vandoolaeghe E., Meltzer H.Y., De Ley M., et al. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr Res 1996, 21:39-50.
20. Maes M., Bosmans E., Kenis G., De Jong R., Smith R.S., Meltzer H.Y. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 1997, 26:221-225.
21. Maes M., Bocchio C.L., Bignotti S., Battisa T.G., Pioli R., Boin F., et al. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol 2000, 10:119-124.
22. Molina-Holgado F., Pinteaux E., Moore J.D., Molina-Holgado E., Guaza C., Gibson R.M., et al. Endogenous interleukin-1 receptor antagonist mediates antiinflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci 2003, 23:6470-6474.
23. Mueser K.T., Drake R.E., Wallach M.A. Dual diagnosis: a review of etiological theories. Addict Behav 1998, 23:717-734.
24. Müller N., Riedel M., Gruber R., Ackenheil M., Schwarz M.J. The immune system and schizophrenia: an integrative view. Ann. N.Y. Acad Sci 2000, 917:456-467.
25. Naudin J., Capo C., Giusano B., Mège J.L., Azorin J.M. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia?. Schizophr Res 1997, 26:227-233.
26. Negrete J.C. Clinical aspects of substance abuse in persons with schizophrenia. Can J Psychiatry 2003, 48:14-21.
27. Pollmächer T., Hinze-Selch D., Mullington J. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 1996, 16:403-409.
28. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008, 63:801-808.
29. Potvin S., Kouassi E., Lipp O., Bouchard R.H., Roy M.A., Demers M.F., et al. Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. J Psychopharmacol 2008, 22:262-269.
30. Potvin S., Stip E., Lipp O., Mancini-Marië A., Élie R., Roy M.A., et al. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorder: an open-label trial. Curr Med Res Opin 2006, 22:1277-1285.
31. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990, 264:2511-2518.
32. Rogers T.J. Immunology as it pertains to drugs of abuse, AIDS and the neuroimmune axis: mediators and traffic. J Neuroimmune Pharmacol 2011, 6:20-27.
33. Rubin L.A., Nelson D.L. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med 1990, 113:619-627.
34. Sirota P., Meiman M., Herschko R., Bessler H. Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients. Psychiatry Res 2005, 134:151-159.
35. Sobell L.C., Sobell M.B. Timeline follow-back: a technique for assessing self-reported alcohol consumption. Measuring alcohol consumptions: psychosocial and biochemical methods 1992, 41-72. Humana Press, Towota. R.Z. Littren, J.P. Allen (Eds.).
36. Strous R.D., Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun 2006, 27:71-80.
37. Zhang X.Y., Zhou D.F., Qi L.Y., Chen S., Cao L.Y., Chen da C., et al. Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics. Psychopharmacology (Berl) 2009, 204:177-184.